CardiologyOnline.net

Cardiology Xagena

Search results for "Apixaban"

New interim findings from a phase 2 proof-of-concept study of an investigational factor Xa inhibitor antidote, Andexanet alfa, in healthy volunteers who received the factor Xa inhibitor Apixaban ( Eli ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa ( Dabigat ...


Apixaban ( Eliquis ), an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.In the randomized, double-blind study ( AMPLIFY ), researchers have ...


Anticoagulant treatment with vitamin K antagonists ( VKAs ) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation ...


For patients with atrial fibrillation or atrial flutter of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown, anticoagulation with Warfarin ( INR 2.0 to 3.0 ) is recom ...


Bristol-Myers Squibb ( BMS ) and Pfizer have announced results of a pre-specified subanalysis of the phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the effica ...


Results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial ( Apixaban after the initial Management ofPuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXT ...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


Amiodarone ( Cordarone ) is an effective medication in preventing atrial fibrillation ( AF ), but it interferes with the metabolism of Warfarin ( Coumadin ). A study has examined the association of ...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis ) show similar efficacy for stroke prevention in patients with atrial fibrillati ...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial fibrillation ( NVAF ) w ...


A study has compared efficacy and safety among novel oral anticoagulants ( NOACs ), which have not been directly compared in randomized control trials to date. Investigators performed network meta- ...


In the Apixaban for Prevention of Acute Ischemic Events ( APPRAISE-2 ) trial, the use of Apixaban ( Eliquis ), when compared with placebo, in high-risk patients with a recent acute coronary syndrome ( ...


Non-vitamin K antagonist oral anticoagulants ( NOACs ) are efficacious and safe antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic events is clinically perce ...


Apixaban ( Eliquis ), a direct factor Xa inhibitor approved for thromboembolic prophylaxis in patients with non-valvular atrial fibrillation, is increasingly used in patients undergoing catheter ablat ...